RxDoctor Payments Data

Marcia Favali, MD

Family Medicine · Terre Haute, INNPI 1154437382

Payments from drug & device makers

$6,045in general payments, 2019–2025

Across 287 payments — averaging $21.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$1K
  • Lilly USA, LLC$609
  • AstraZeneca$511
  • GSK$237
  • Amgen$235
  • plus $2K from 33 others

What the payments were for

  • Food & beverage$6,025100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,045 in reported general payments places this provider in the 85th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$81,057
Medicare patients
211
Services billed
1,060

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide51$57,267
JardianceEmpagliflozin35$30,551
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$29,036
OzempicSemaglutide29$27,432
JanuviaSitagliptin Phosphate36$23,563
FarxigaDapagliflozin Propanediol25$21,824
TrulicityDulaglutide17$20,078
MyrbetriqMirabegron100$18,480
EliquisApixaban31$13,976
TradjentaLinagliptin16$13,897
LinzessLinaclotide18$10,703
Xigduo XrDapaglifloz Propaned/Metformin13$7,372
Spiriva RespimatTiotropium Bromide12$7,151
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen205$6,197
CombiganBrimonidine Tartrate/Timolol13$4,937

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$609$77,34568 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$98$51,59963 claims
GSKTrelegy Ellipta, Shingrix$237$32,50849 claims
Novo NordiskOzempic$1,073$27,43229 claims
AstraZenecaFarxiga$511$21,82425 claims
Astellas Pharma US IncMyrbetriq$206$18,480100 claims
AbbVieLinzess, Combigan, Synthroid$1,044$18,11470 claims
PfizerEliquis$111$13,97631 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$33$3,353371 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Terre Haute

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →